Detailed financial statements for Alkermes plc (ALKS): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Analysis Summary
Alkermes plc reported revenue of $1.48B in the most recent fiscal year, growing at a 5-year CAGR of 7.3%.
Trailing-twelve-month margins: gross margin 84.6%, operating margin 7.0%, net margin 4.0%. Free cash flow grew at 63.9% CAGR over 5 years.
Balance sheet quality for ALKS: current ratio of 3.5, net cash position of $1.25B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $480.3M represents 199% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $745.7M | $903.4M | $1.09B | $1.17B | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Cost of Revenue | $132.1M | $154.7M | $176.4M | $180.4M | $178.3M | $197.3M | $218.1M | $253.0M | $245.3M | $196.5M |
| Gross Profit | $613.6M | $748.6M | $917.9M | $990.6M | $860.4M | $976.4M | $893.7M | $1.41B | $1.31B | $1.28B |
| Research & Development | $387.1M | $412.9M | $425.4M | $512.8M | $394.6M | $290.9M | $272.7M | $270.8M | $245.3M | $324.0M |
| Selling, General & Admin | $374.1M | $421.6M | $526.4M | $599.4M | $538.8M | $549.6M | $590.8M | $689.8M | $645.2M | $714.5M |
| Operating Expenses | $822.2M | $896.5M | $1.02B | $1.17B | $972.9M | $878.7M | $899.8M | $996.2M | $891.7M | $1.03B |
| Operating Income | -$208.7M | -$147.9M | -$99.1M | -$175.5M | -$112.4M | $97.7M | -$6.1M | $414.1M | $420.6M | $254.0M |
| EBITDA | -$105.2M | -$32.7M | -$7.9M | -$103.0M | -$6.0M | $177.6M | $59.8M | $519.5M | $494.9M | $330.9M |
| Interest Expense | $14.9M | $12.0M | $15.4M | $13.6M | $8.7M | $11.2M | $13.0M | $23.0M | $22.6M | $12.3M |
| Pre-tax Income | -$214.4M | -$143.3M | -$127.0M | -$197.1M | -$96.5M | $87.7M | -$31.1M | $421.5M | $443.8M | $291.4M |
| Income Tax | -$5.9M | $14.7M | $12.3M | -$436000 | $14.3M | $11.3M | $2.0M | -$97.6M | $71.6M | $49.8M |
| Net Income | -$208.4M | -$157.9M | -$139.3M | -$196.6M | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| EPS | $-1.38 | $-1.03 | $-0.90 | $-1.25 | $-0.70 | $-0.30 | $-0.97 | $2.14 | $2.22 | $1.47 |
| EPS (Diluted) | $-1.38 | $-1.03 | $-0.90 | $-1.25 | $-0.70 | $-0.30 | $-0.97 | $2.10 | $2.17 | $1.43 |
| Shares Outstanding (Diluted) | $151.5M | $153.4M | $155.1M | $157.1M | $158.8M | $160.9M | $163.7M | $169.7M | $169.2M | $168.7M |
Income Statement (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Revenue | $394.2M | $384.5M | $392.9M | $496.0M |
| Gross Profit | $342.6M | $338.3M | $331.3M | $397.9M |
| Operating Income | $89.1M | $58.1M | -$48.3M | $18.4M |
| EBITDA | $108.8M | $76.5M | -$21.6M | $54.3M |
| Net Income | $82.8M | $49.3M | -$66.5M | $501000 |
| EPS | $0.50 | $0.30 | $-0.40 | $0.00 |
| EPS (Diluted) | $0.49 | $0.29 | $-0.40 | $0.00 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $186.4M | $191.3M | $266.8M | $203.8M | $273.0M | $337.5M | $292.5M | $457.5M | $291.1M | $1.12B |
| Short-term Investments | $310.9M | $242.2M | $272.5M | $331.2M | $362.1M | $198.8M | $316.0M | $316.0M | $460.5M | $199.6M |
| Receivables | $191.1M | $233.6M | $300.5M | $265.5M | $289.5M | $326.6M | $296.9M | $333.2M | $389.5M | $334.0M |
| Inventory | $63.0M | $93.3M | $90.2M | $101.8M | $125.7M | $150.3M | $181.4M | $186.4M | $182.9M | $196.6M |
| Total Current Assets | $912.6M | $966.1M | $983.3M | $962.0M | $1.11B | $1.06B | $1.13B | $1.49B | $1.42B | $1.93B |
| Property, Plant & Equipment | $264.8M | $284.7M | $310.0M | $374.5M | $481.7M | $456.7M | $320.5M | $318.4M | $311.8M | $298.9M |
| Goodwill | $92.9M | $92.9M | $92.9M | $92.9M | $92.9M | $92.9M | $83.0M | $83.0M | $83.0M | 0 |
| Intangible Assets | $318.2M | $256.2M | $191.0M | $150.6M | $111.2M | $74.0M | $37.7M | $2.0M | $890000 | $83.8M |
| Total Assets | $1.73B | $1.80B | $1.83B | $1.81B | $1.95B | $2.02B | $1.96B | $2.14B | $2.06B | $2.53B |
| Accounts Payable | $46.3M | $55.5M | $39.8M | $54.3M | $46.0M | $55.7M | $32.8M | $65.6M | $45.6M | $108.0M |
| Short-term Debt | $3.0M | $3.0M | $2.8M | $2.8M | $2.8M | $3.0M | $3.0M | $3.0M | 0 | $6.7M |
| Total Current Liabilities | $212.0M | $291.1M | $339.8M | $391.1M | $438.3M | $471.3M | $497.7M | $520.2M | $465.2M | $543.4M |
| Long-term Debt | $280.7M | $278.4M | $276.5M | $274.3M | $272.1M | $292.8M | $290.3M | $287.7M | 0 | 0 |
| Total Liabilities | $516.9M | $594.4M | $653.7M | $720.0M | $882.7M | $911.9M | $920.2M | $933.5M | $590.6M | $711.0M |
| Retained Earnings | -$947.9M | -$1.04B | -$1.19B | -$1.38B | -$1.49B | -$1.54B | -$1.70B | -$1.34B | -$976.5M | -$734.8M |
| Total Equity | $1.21B | $1.20B | $1.17B | $1.09B | $1.07B | $1.11B | $1.04B | $1.20B | $1.46B | $1.82B |
| Total Debt | $283.7M | $281.4M | $279.3M | $290.9M | $410.2M | $416.2M | $379.4M | $372.2M | $75.5M | $70.0M |
| Net Debt | -$335.5M | -$309.3M | -$260.0M | -$244.0M | -$224.9M | -$120.1M | -$229.0M | -$401.3M | -$676.1M | -$1.25B |
| Working Capital | $700.6M | $674.9M | $643.5M | $570.9M | $672.7M | $590.9M | $632.6M | $965.3M | $950.2M | $1.39B |
Balance Sheet (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Cash & Equivalents | $616.4M | $1.12B | $351.6M | $511.5M |
| Total Assets | $2.33B | $2.53B | $4.26B | $4.39B |
| Total Liabilities | $596.1M | $711.0M | $2.51B | $2.58B |
| Total Equity | $1.73B | $1.82B | $1.75B | $1.81B |
| Total Debt | $71.6M | $70.0M | $1.58B | $1.57B |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$208.4M | -$157.9M | -$139.3M | -$196.6M | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| Depreciation & Amortization | $94.3M | $98.5M | $103.7M | $80.4M | $81.9M | $78.7M | $77.9M | $74.9M | $28.5M | $27.2M |
| Stock-based Compensation | $94.4M | $83.9M | $105.4M | $101.0M | $90.2M | $87.6M | $94.3M | $100.9M | $96.6M | $98.7M |
| Change in Working Capital | -$27.2M | -$4.9M | -$7.4M | $65.4M | $13.1M | -$25.5M | $12.7M | -$36.7M | -$98.2M | $119.1M |
| Operating Cash Flow | -$63.8M | $19.2M | $99.3M | $72.1M | $82.8M | $101.7M | $21.0M | $401.4M | $439.1M | $520.8M |
| Capital Expenditure | -$43.7M | -$51.3M | -$69.4M | -$90.9M | -$42.2M | -$29.0M | -$38.3M | -$48.0M | -$33.5M | -$40.4M |
| Acquisitions | -$15.0M | $162000 | $507000 | -$8.0M | $2.8M | -$713000 | $485000 | 0 | $98.0M | $2.8M |
| Stock Repurchased | -$13.5M | -$16.4M | -$19.6M | -$9.3M | -$7.7M | -$16.6M | -$18.2M | -$28.5M | -$200.3M | -$31.0M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$107.5M | -$32.1M | $29.9M | -$18.9M | $40.6M | $72.7M | -$17.2M | $353.3M | $405.6M | $480.3M |
Cash Flow (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Operating Cash Flow | $101.7M | $170.1M | -$165.7M | $145.2M |
| Capital Expenditure | -$17.3M | $20000 | -$4.1M | -$8.1M |
| Free Cash Flow | $84.4M | $170.1M | -$169.8M | $137.0M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Stock-based Compensation | $24.7M | -$72.4M | 0 | $31.1M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +21.1% | +21.1% | +7.0% | -11.3% | +13.0% | -5.3% | +49.6% | -6.4% | -5.2% | |
| Net Income Growth (YoY) | +24.2% | +11.8% | -41.1% | +43.6% | +56.6% | -228.6% | +324.8% | +3.2% | -34.2% | |
| EPS Growth (YoY) | +25.4% | +12.6% | -38.9% | +44.0% | +57.1% | -223.3% | +320.6% | +3.7% | -33.8% | |
| Shares Change (YoY) | +1.3% | +1.1% | +1.3% | +1.1% | +1.3% | +1.7% | +3.7% | -0.3% | -0.3% | |
| FCF Growth (YoY) | +70.1% | +193.0% | -163.2% | +315.3% | +79.0% | -123.7% | +2152.8% | +14.8% | +18.4% | |
| Gross Margin | 82.3% | 82.9% | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% |
| Operating Margin | -28.0% | -16.4% | -9.1% | -15.0% | -10.8% | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% |
| EBITDA Margin | -14.1% | -3.6% | -0.7% | -8.8% | -0.6% | 15.1% | 5.4% | 31.2% | 31.8% | 22.4% |
| Net Margin | -28.0% | -17.5% | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
| FCF Margin | -14.4% | -3.6% | 2.7% | -1.6% | 3.9% | 6.2% | -1.5% | 21.2% | 26.0% | 32.5% |
| Effective Tax Rate | 2.8% | -10.2% | -9.7% | 0.2% | -14.8% | 12.9% | -6.5% | -23.2% | 16.1% | 17.1% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-0.71 | $-0.21 | $0.19 | $-0.12 | $0.26 | $0.45 | $-0.11 | $2.08 | $2.40 | $2.85 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $151.5M | $153.4M | $155.1M | $157.1M | $158.8M | $160.9M | $163.7M | $166.2M | $165.4M | $164.7M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Gross Margin | 84.56% |
| Operating Margin | 7.03% |
| Net Margin | 3.97% |
Financial Health
| Debt / Equity | 0.87 |
| Current Ratio | 2.30 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -40.28 | -53.14 | -32.79 | -16.32 | -28.50 | -77.53 | -26.94 | 12.96 | 12.95 | 19.03 |
| P/B | 6.96 | 6.98 | 3.91 | 2.95 | 2.97 | 3.36 | 4.10 | 3.83 | 3.25 | 2.53 |
| P/S | 11.29 | 9.29 | 4.18 | 2.74 | 3.05 | 3.19 | 3.85 | 2.77 | 3.05 | 3.12 |
| Gross Margin | 82.3% | 82.9% | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% |
| Operating Margin | -28.0% | -16.4% | -9.1% | -15.0% | -10.8% | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% |
| Net Margin | -28.0% | -17.5% | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
Related companies: ACAD · ACLX · AKRO · ARWR · CRSP · KYMR · PCVX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks